PROgnostic Signature in stage II colon cancer (CC) patients enrolled in the phase III clinical trial TOSCA: PROSIT study

被引：0
|
作者：
Puccini, A. [1 ,2 ]
Ferrando, L. [3 ]
Mazzarella, L. [4 ]
Frige, G. [5 ]
Pessino, A. [6 ]
Pastorino, A. [7 ]
Martelli, V. [8 ]
Garuti, A. [2 ]
Ballestrero, A. [2 ]
Torri, V. [9 ]
Labianca, R. [10 ]
Fassan, M. [11 ]
Lonardi, S. [12 ]
Zoppoli, G. [13 ,14 ]
Sobrero, A. [15 ]
机构：
[1] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Rozzano, Italy
[2] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Rozzano, Italy
[3] IRCCS Osped Policlin San Martino, Dept Internal Med, Genoa, Italy
[4] IEO Ist Europeo Oncol IRCCS, New Drug Dev, Expt Oncol, Milan, Italy
[5] IEO Ist Europeo Oncol, Expt Oncol, Milan, Italy
[6] IRCCS Osped Policlin San Martino, Hematooncol Dept, Genoa, Italy
[7] IRCCS Osped Policlin San Martino, Dept Med Oncol, Genoa, Italy
[8] IRCCS Osped Policlin San Martino, Dipartimento Oncol Med 1, Genoa, Italy
[9] Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy
[10] ASST Papa Giovanni XXIII, Prov Dept Oncol, Bergamo, Italy
[11] Azienda Univ Osped Padova, Padua, Italy
[12] IOV Ist Oncol Veneto IRCCS, Dept Oncol, Padua, Italy
[13] Univ Genoa, Dept Internal Med, Genoa, Italy
[14] Osped Policlin San Martino IRCCS DiMI, Genoa, Italy
[15] IRCCS Osped Policlin San Martino, Dept Med Oncol, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
25P
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [1] Highly prognostic signature for stage II colon cancer from the TOSCA trial: The PROSIT study
    Puccini, Alberto
    Ferrando, Lorenzo
    Mazzarella, Luca
    Frige, Gianmaria
    Pessino, Anna Maria
    Pastorino, Alessandro
    Martelli, Valentino
    Garuti, Anna
    Di Antonio, Veronica
    Ballestrero, Alberto
    Torri, Valter
    Labianca, Roberto
    Fassan, Matteo
    Lonardi, Sara
    Zoppoli, Gabriele
    Sobrero, Alberto F.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Metformin and risk recurrence in resected stage II/III colon cancer (CC) patients (pts): subgroup analysis from the TOSCA trial
    Di Bartolomeo, M.
    Rosato, G.
    Banzi, M.
    Pella, N.
    Zampino, M. G.
    Rimassa, L.
    Maiello, E.
    Marchetti, P.
    Lonardi, S.
    Labianca, R.
    Zaniboni, A.
    Sobrero, A.
    Ferrari, D.
    Bidoli, P.
    Iaffaioli, V.
    De Placido, S.
    Frassineti, L.
    Frustaci, S.
    Nicolini, M.
    Vernieri, C.
    Galli, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial
    Basile, Debora
    Rosati, Gerardo
    Bergamo, Francesca
    Garattini, Silvio Ken
    Banzi, Maria
    Zampino, Maria
    Bozzarelli, Silvia
    Marchetti, Paolo
    Galli, Fabio
    Galli, Francesca
    Longarini, Raffaella
    Zaniboni, Alberto
    Ferrari, Daris
    De Placido, Sabino
    Frassineti, Luca Giovanni
    Nicolini, Mario
    Cinieri, Saverio
    Priscindiaro, Michele
    Ziranu, Pina
    Caccialanza, Riccardo
    Pastorino, Alessandro
    Mosconi, Stefania
    Aprile, Giuseppe
    CLINICAL COLORECTAL CANCER, 2023, 22 (02) : 190 - 198
  • [4] Prognostic and predictive value of a lncRNA signature in patients with stage II colon cancer
    Ailin Qu
    Qian Wang
    Qing Chang
    Jingkang Liu
    Yongmei Yang
    Xin Zhang
    Yanli Zhang
    Xiaoshi Zhang
    Hongchun Wang
    Yi Zhang
    Scientific Reports, 13
  • [5] Prognostic and predictive value of a lncRNA signature in patients with stage II colon cancer
    Qu, Ailin
    Wang, Qian
    Chang, Qing
    Liu, Jingkang
    Yang, Yongmei
    Zhang, Xin
    Zhang, Yanli
    Zhang, Xiaoshi
    Wang, Hongchun
    Zhang, Yi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [6] Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer
    Jacob, Havjin
    Stanisavljevic, Luka
    Storli, Kristian Eeg
    Hestetun, Kjersti E.
    Dahl, Olav
    Myklebust, Mette P.
    ONCOTARGET, 2017, 8 (50) : 87837 - 87847
  • [7] CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial
    Rothe, Francoise
    Maetens, Marion
    Rouas, Ghizlane
    Paesmans, Marianne
    Van den Eynde, Marc
    Van Laethem, Jean-Luc
    Vergauwe, Philippe
    Deboever, Guido
    Bareche, Yacine
    Vandeputte, Caroline
    Ignatiadis, Michail
    Hendlisz, Alain
    BMC CANCER, 2019, 19 (1)
  • [8] CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial
    Françoise Rothé
    Marion Maetens
    Ghizlane Rouas
    Marianne Paesmans
    Marc Van den Eynde
    Jean-Luc Van Laethem
    Philippe Vergauwe
    Guido Deboever
    Yacine Bareche
    Caroline Vandeputte
    Michail Ignatiadis
    Alain Hendlisz
    BMC Cancer, 19
  • [9] Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial
    Ruzzo, A.
    Galli, F.
    Galli, F.
    Rulli, E.
    Lonardi, S.
    Zagonel, V.
    Ronzoni, M.
    Ionta, M. T.
    Pella, N.
    Mucciarini, C.
    Labianca, R.
    Veltri, E.
    Sozzi, P.
    Barni, S.
    Nicolini, M.
    Biondi, E.
    Bramati, A.
    Turci, D.
    Buscaglia, M.
    Magnani, M.
    Graziano, F.
    ANNALS OF ONCOLOGY, 2017, 28 : 4 - 5
  • [10] Independent Validation of a Prognostic Genomic Signature (ColoPrint) for Patients With Stage II Colon Cancer
    Maak, Matthias
    Simon, Iris
    Nitsche, Ulrich
    Roepman, Paul
    Snel, Mireille
    Glas, Annuska M.
    Schuster, Tibor
    Keller, Gisela
    Zeestraten, Eliane
    Goossens, Ines
    Janssen, Klaus-Peter
    Friess, Helmut
    Rosenberg, Robert
    ANNALS OF SURGERY, 2013, 257 (06) : 1053 - 1058
12345